Xilio Therapeutics (XLO) Current Assets (2020 - 2026)

Xilio Therapeutics (XLO) has 7 years of Current Assets data on file, last reported at $154.2 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets rose 65.46% year-over-year to $154.2 million; the trailing twelve-month figure through Mar 2026 stood at $154.2 million (up 65.46% YoY), and the FY2025 full-year result was $145.0 million, up 140.77% from the prior year.
• Current Assets rose to $154.2 million in Q1 2026, from $145.0 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $181.1 million in Q1 2022 to a low of $48.1 million in Q4 2023.
• A 5-year average of $106.5 million and a median of $97.0 million in 2023 frame the typical range for Current Assets.
• Across the five-year window, Current Assets tumbled 61.34% in 2023 and jumped 140.77% in 2025, its largest moves.
• Tracing XLO's Current Assets over 5 years: stood at $124.5 million in 2022, then plunged by 61.34% to $48.1 million in 2023, then increased by 25.16% to $60.2 million in 2024, then jumped by 140.77% to $145.0 million in 2025, then rose by 6.33% to $154.2 million in 2026.
• Business Quant data shows XLO's Current Assets at $154.2 million in Q1 2026, $145.0 million in Q4 2025, and $124.1 million in Q3 2025.